Literature DB >> 14700272

Tuning the rheostat of the myelopoietic system via Fas and TRAIL.

Richard Greil1, Gabriele Anether, Karin Johrer, Inge Tinhofer.   

Abstract

During the last decade, the concerted effort of numerous scientific groups has expanded our understanding of the finely tuned network present within bone marrow for the regulation of the hematopoietic system. This network, comprising humoral and cellular cross talk, is responsible for the adaptation of hematopoietic populations to demands as they arise. Major components of this control system are death receptors and their specific ligands, which eliminate superfluous cells once they have fulfilled their respective functions. The important role of Fas (CD95/Apo-1), one member of this death receptor family, in the regulation of T- and B-cell functions has been established. Alteration of Fas expression and/or function in lymphoid cells may contribute to the development of autoimmunity and/or neoplastic diseases. In addition to controlling lymphoid compartments, Fas is also involved in the regulation of myeloid cell functions. More recently, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its specific receptors (TRAIL-R) have been identified as further members of this death receptor/ligand family. The TRAIL-R/TRAIL system is of vital importance for the maturation and functioning of immune effector cells of lymphoid, as well as myeloid, origin. In the present review, we have summarized current knowledge about both death receptor/ligand systems in the expansion and functioning of cells from the myeloid compartments, highlighted their role in normal hematopoiesis, and assessed their alterations in pathologic or neoplastic conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14700272     DOI: 10.1615/critrevimmunol.v23.i4.30

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  2 in total

Review 1.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

2.  Essential roles of PKA, iNOS, CD95/CD95L, and terminal caspases in suppression of eosinopoiesis by PGE2 and other cAMP-elevating agents.

Authors:  Bianca de Luca; Pedro Xavier-Elsas; Mônica Barradas; Ricardo A Luz; Túlio Queto; Carla Jones; Maria Augusta Arruda; Thiago Mattar Cunha; Fernando Queiroz Cunha; Maria Ignez Gaspar-Elsas
Journal:  ScientificWorldJournal       Date:  2013-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.